Navigation Links
Shining the soothing light
Date:10/21/2013

Almost all patients suffering from head and neck squamous cell carcinoma (HNSCC) develop canker sores, a complication resulting from different modalities of treatment, namely stem cell transplantation, chemotherapy, and radiotherapy. Canker sore is divided in five grades (zero to four) by the World Health Organization (WHO), with severe cases (grades 3 and 4) being associated with pain, weight loss, poor quality of life, and higher hospital costs due to increased healthcare needs. Severe canker sore can also lead to treatment interruption, which may decrease the patient's chances of surviving the cancer.

No effective preventative strategy is currently available for canker sore, but prospective trials of low-level laser therapy (LLLT) done in HNSCC patients undergoing chemoradiotherapy showed promising results. However, additional trials detected a high incidence of canker sore among patients, leaving the question of whether LLLT can effectively prevent canker sore still open.

Now, a group of scientists led by Dr. Heliton Spindola Antunes at the National Cancer Institute (INCA) in Rio de Janeiro, Brazil, has successfully performed a definitive trial showing that LLLT reduces the occurrence of canker sore in HNSCC patients undergoing concurrent chemoradiotherapy and improves patient's quality of life.

The trial was performed with 94 HNSCC patients undergoing chemoradiotherapy. They were divided into two groups of 47 individuals, one of which received LLLT while the other received placebo. Researchers observed a significant difference in the incidence of canker sore grades 3 and 4 between groups. For instance, while in the group of patients receiving LLLT only three patients developed severe cases of canker sore, in the group receiving the placebo this number was 19. There were also significant differences in the absence of canker sore (grades 0-1), with the LLLT group having 59.6% of patients free of canker sore as opposed to 21.3% in the placebo group. The LLLT group had less severe oral pain and, as a result, used fewer opioid analgesics. They were also less likely to require gastrostomy (a surgical opening into the stomach for nutritional support) throughout the cancer treatment.

"For ethical reasons," says Dr Antunes, "all patients who developed canker sore grades 3 or 4 in the placebo arm were then offered the option of receiving LLLT. They all improved to grade 2 or lower, supporting the evidence that LLLT is an effective choice to prevent or treat canker sore in these patients."


'/>"/>

Contact: Heliton Spindola Antunes
hspindola@inca.gov.br
55-213-207-6597
Publicase Comunicao Cientfica
Source:Eurekalert

Related medicine news :

1. Mother-Baby Sleep Experts Offer Tips for Soothing Crying Babies, Giving Exhausted Mothers Alternatives to Crying It Out
2. Soothing sounds during cataract surgery reduces patient anxiety
3. Cataract Patients Relax to a Soothing Beat, Study Says
4. Nationwide Title Clearing, Inc. Prepares for “Light the Night Walk” for Cancer Fundraising
5. Into Action Treatment Sponsors NOPE Annual Candlelight Vigil
6. Specialized Lighting Products Designed by Daylight Now Offered by Rehabmart.com
7. Deepak Chopra Introduces Dream Weaver App for Smartphones with Strobe Lights, Making It Easy to Experience the Benefits of Meditation & Deep Relaxation Automatically
8. Mesothelioma Awareness Day Sheds Light on Deadly Cancer
9. Joseph Gordon-Levitt’s “Don Jon” Spotlights the Health Problems with Porn
10. Go Healthy Next Announces the SaunaFix, a Portable Sauna Featuring Near Infrared Light Therapy
11. FHFA Highlights Homeowners HARP Refinancing: Eligibility Is Easier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 2017 , ... The first-ever National Heart Valve Disease Awareness ... join together to increase recognition about the risks of heart valve disease (HVD) ... mark a nationwide movement to raise awareness about a disease that has not ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Centers for Medicare & ... practices in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate ... Reauthorization Act of 2015 (MACRA). , This technical assistance, authorized and funded ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a leader in ... the delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians ... tissue synthesis and provide a faster and more efficient healing process. There are ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... company, launched a new media platform connecting healthcare technology professionals and other key ... followed by a quarterly publication starting on March 1, announced Michael J. Hennessy, ...
(Date:2/22/2017)... ... , ... The SeniorCare Investor will host an important webinar— Seniors Housing M&A: ... 1:00 PM ET. A recording of the webinar will also be made available following ... you want to find out what really happened in the seniors housing and care ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Research and Markets has announced the addition of the ... to their offering. ... Dermatological conditions are one of the most ... US population suffers from at least one active skin condition. ... has remained saturated with established and generic products. However, the ...
(Date:2/22/2017)... Research and Markets has announced the addition of ... Small Molecule Drugs), By Route of Administration (Systemic, Topical), By ... report to their offering. ... The global psoriasis drugs market is anticipated ... report provides a detailed analysis of the current and future ...
(Date:2/22/2017)... , Feb. 22, 2017  Tri-Source Pharma announced today ... A series of newly appointed positions were added to ... CEO, Robert DiCrisci , in the implementation and ... management of the recently consolidated subsidiary companies. ... team will be composed of the following eight members ...
Breaking Medicine Technology: